Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction

References

• Tomada N, Oliveira R, Tomada I, Vendeira P, Neves D. Comparative ultrastructural study of human corpus cavernosum during ageing. Microsc Microanal 2008;14:S3152–S3155.
   Google Scholar
• Cordeiro AL, Figueiredo A, Godinho F, Martins I, Vendeira P, Almeida H, Neves D. Ultrastructural characterization of corpus cavernosum of ageing, orchidectomy and diabetes rat experimental models. Microsc Microanal 2008;14:S397–S398.
   Google Scholar
• Burnett AL, Nelson RJ, Calvin DC, Liu JX, Demas GE, Klein SL, et al. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996; 2:288–296.
   PubMed Web of Science ®Google Scholar
• Hurt KJ, Sezen SF, Lagoda GF, Musicki B, Rameau GA, Snyder SH, Burnett AL. Cyclic AMP-dependent phosphorylation of neuronal nitric oxide synthase mediates penile erection. Proc Natl Acad Sci USA 2012;109:16624–16629.
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;31: 843–850.
   Google Scholar
• Kaya C, Uslu Z, Karaman I. Is endothelial function impaired in erectile dysfunction patients?Int J Impot Res 2006;18: 55–60.
   PubMed Web of Science ®Google Scholar
• Shamloul R, Ghanem H. Erectile dysfunction. 2013;381: 153–165.
   Google Scholar
• Goldstein I. The association of ED (erectile dysfunction) with ED (endothelium dysfunction) in the international journal of impotence research: The journal of sexual medicine. Int J Impot Res 2003;15:229–230.
   PubMedGoogle Scholar
• Guay AT. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol Metabol Clin N Am 2007;36:453–463.
   PubMedGoogle Scholar
• Ayta IA, Mckinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84: 50–56.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54–61.
   PubMed Web of Science ®Google Scholar
• Ghalayini IF, Al-Ghazo MA, Al-Azab R, Bani-Hani I, Matani YS, Barham AE, et al. Erectile dysfunction in a Mediterranean country: Results of an epidemiological survey of a representative sample of men. Int J Impot Res 2010; 22:196–203.
   PubMed Web of Science ®Google Scholar
• Ponholzer A, Temml C, Mock K, Marzlaekm M, Obermayr R, Maderbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005;47:80–86.
   PubMed Web of Science ®Google Scholar
• Thorve VS, Kshirsagar AD, Vyawahare NS, Joshi VS, Ingale KG, Mohite RJ. Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management. J Diabetes Complications 2011;25:129–136.
   PubMed Web of Science ®Google Scholar
• Lewis RW. Epidemiology of erectile dysfunction. Urol Clin North Am 1996;28:209–216.
   Google Scholar
• Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: Erectile Dysfunction Among English-Speakers. J Sex Med. 2012 [Epub ahead of print].
   Google Scholar
• Lusis AJ. Atherosclerosis. Nature 2000;407:233–241.
   PubMed Web of Science ®Google Scholar
• Cheitlin CMD. Erectile dysfunction: the earliest sign of generalized vascular disease?J Am Coll Cardiol 2004;43: 185–186.
   PubMed Web of Science ®Google Scholar
• Stadtman ER. Protein oxidation and aging. Science 1992;257:1220–1224.
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000;26:163–176.
   PubMed Web of Science ®Google Scholar
• Silva FH, Mónica FZ, Báu FR, Brugnerotto AF, Priviero FB, Toque HA, Antunes E. Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-gged rats: prevention by antioxidant therapy. J Sex Med2013 [Epub ahead of print].
   Google Scholar
• Figueiredo A, Cordeiro AL, Tomada N, Tomada I, Rodrigues A, Gouveia A, Neves D. Real-time PCR study of Ang1, Ang2, Tie-2, VEGF and KDR expression in human erectile tissue during aging. J Sex Med 2011;8:1341–1351.
   PubMed Web of Science ®Google Scholar
• Tomada N, Tomada I, Vendeira P, Cruz F, Neves D. Characterization of VEGF and Angiopoietins expression in human corpus cavernosum during aging. J Sex Med 2011; 7:1410–1418.
   Google Scholar
• Baraibar MA, Liu L, Ahmed EK, Friguet B. Protein oxidative damage at the crossroads of cellular senescence, aging and aging-related diseases. Oxid Med Cell Longev2012 [Epub ahead of print].
   Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820.
   PubMed Web of Science ®Google Scholar
• Vlassara H, Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning?Rev Endocr Metab Disord 2004;5:181–188.
   PubMedGoogle Scholar
• Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999;10:157–167.
   PubMed Web of Science ®Google Scholar
• Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009;73:411–418.
   PubMed Web of Science ®Google Scholar
• Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997; 50:1016–1026.
   PubMed Web of Science ®Google Scholar
• Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001;87:402–407.
   PubMed Web of Science ®Google Scholar
• Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004;53:131–142.
   PubMed Web of Science ®Google Scholar
• Jiaan DB, Seftel AD, Fogarty J, Hampel N, Cruz W, Pomerantz J, et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995;13:369–375.
   PubMed Web of Science ®Google Scholar
• Hipkiss AR. Accumulation of altered proteins and ageing: causes and effects. Expt Gerontolol 2006;41:464–473.
   PubMed Web of Science ®Google Scholar
• Schöneich C. Protein modification in aging: an update. Exp Gerontol 2006;41807–41812.
   Google Scholar
• Maillard LC. Action des acides amines sur les sucres: formation des mélanoides par voie méthodique. C R Acad Sci 1912;154:66–68.
   Google Scholar
• Ahem N, Thornally PJ. Advanced glycation end-products: what is their relevance to diabetic complications?Diabetes Obes Metab 2007;9:233–245.
   PubMedGoogle Scholar
• Rabbani N, Thornalley PJ. Glycation research in aminoacids: a place to call home. Aminoacids 2012;42:1087–1096.
   PubMed Web of Science ®Google Scholar
• Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation – A mini-review. Gerontology 2012;58: 227–237.
   PubMed Web of Science ®Google Scholar
• Lyons T, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a carbonyl stress hypothesis. Diabetes Rev 1997;5: 365–391.
   Google Scholar
• Degenhardt TP, Thorpe SR, Baynes JW. Chemical modification of proteins by methylglyoxal. Cell Mol Biol 1998; 44:1139–1145.
   PubMed Web of Science ®Google Scholar
• Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Sem Cell Dev Biol 2011;22:293–301.
   PubMed Web of Science ®Google Scholar
• He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999;48:1308–1315.
   PubMed Web of Science ®Google Scholar
• Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441–9445.
   PubMed Web of Science ®Google Scholar
• Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, et al. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992;258:651–653.
   PubMed Web of Science ®Google Scholar
• Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie Biologie 2006;54:405–419.
   PubMed Web of Science ®Google Scholar
• Baumann M. Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. J Am Soc Hypertens 2012;6:427–435.
   PubMed Web of Science ®Google Scholar
• Mizutari K, Ono T, Ikeda K, Kayashima K, Horiuchi S. Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol 1997;108:797–802.
   PubMed Web of Science ®Google Scholar
• Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992;267:12404–12407.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005;6:453–474.
   PubMed Web of Science ®Google Scholar
• Knott HM, Brown BE, Davies MJ, Dean RT. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem 2003;270: 3572–3582.
   PubMedGoogle Scholar
• Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008;118:183–194.
   PubMed Web of Science ®Google Scholar
• Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990;87:9010–9014.
   PubMed Web of Science ®Google Scholar
• Nam MH, Lee HS, Seomun Y, Lee Y, Lee KW. Monocyte-endothelium-smooth muscle cell interaction in co-culture: proliferation and cytokine productions in response to advanced glycation end products. Biochim Biophys Acta 2011;1810:907–912.
   PubMed Web of Science ®Google Scholar
• Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992;90:439–446.
   PubMed Web of Science ®Google Scholar
• Corrêa-Giannella ML, de Azevedo MR, Leroith D, Giannella-Neto D. Fibronectin glycation increases IGF-I induced proliferation of human aortic smooth muscle cells. Diabetol Metab Syndr 2012;4:19.
   PubMedGoogle Scholar
• Cantero AV, Portero-Otin M, Ayala V, Auge N, Sanson M, Elbaz M, et al. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J 2007;21:3096–3106.
   PubMed Web of Science ®Google Scholar
• Nass N, Vogel K, Hofmann B, Presek P, Silber RE, Simm A. Glycation of PDGF results in decreased biological activity. Int J Biochem Cell Biol 2010;42:749–754.
   PubMedGoogle Scholar
• Yang SJ, Chen CY, Chang GD, Wen HC, Chen CY, Chang SC, et al. Activation of Akt by advanced glycation end products (AGEs): involvement of IGF-1 receptor and caveolin-1. PLoS One 2013;8:e58100.
   Google Scholar
• Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44: 108–114.
   PubMed Web of Science ®Google Scholar
• Christ M, Bauersachs J, Liebetrau C, Heck M, Günther A, Wehling M. Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 2002;51:2648–2652.
   PubMed Web of Science ®Google Scholar
• Su J, Lucchesi PA, Gonzalez-Villalobos RA, Palen DI, Rezk BM, Suzuki Y, et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008;28:1432–1438.
   PubMed Web of Science ®Google Scholar
• Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432–438.
   PubMed Web of Science ®Google Scholar
• Sena CM, Matafome P, Crisóstomo J, Rodrigues L, Fernandes R, Pereira P, Seiça RM. Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol Res 2012;65:497–506.
   PubMed Web of Science ®Google Scholar
• Xu B, Ji Y, Yao K, Cao YX, Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin Sci (Lond) 2005;10:439–446.
   Google Scholar
• Lai YL, Aoyama S, Nagai R, Miyoshi N, Ohshima H. Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products. J Clin Biochem Nutr 2010;46:177–185.
   PubMedGoogle Scholar
• Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000;49:1561–1570.
   PubMed Web of Science ®Google Scholar
• Giuseppe C, Ferdinando F, Ciro I, Vincenzo M. Pharmacology of erectile dysfunction in man. Pharmacol Ther 2006;111:400–423.
   PubMedGoogle Scholar
• Aversa A, Basciani S, Visca P, Arizzi M, Gnessi L, Frajese G, Fabbri A. Platelet-derived growth factor (PDGF) and PDGF receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia. J Endocrinol 2001;170:395–402.
   PubMed Web of Science ®Google Scholar
• Vlassara H. The AGE-receptor in the in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001;17: 436–443.
   PubMed Web of Science ®Google Scholar
• Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Nat Acad Sci 2004;101:11767–11772.
   PubMed Web of Science ®Google Scholar
• Cai W, Torreggiani M, Zhu L, Chen X, He JC, Striker GE, Vlassara H. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 2010; 298:C624–C634.
   Google Scholar
• Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A. 2012;109:15888–15893.
   PubMed Web of Science ®Google Scholar
• Tomada I, Tomada N, Almeida H, Neves D. Androgen depletion in humans leads to cavernous tissue reorganization and upregulation of Sirt1-eNOS axis. AGE 2013;35:35–47.
   PubMedGoogle Scholar
• Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A. Identification of galectin-3 as a high- affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634–646.
   PubMed Web of Science ®Google Scholar
• Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One 2013;8:e57915.
   PubMedGoogle Scholar
• Darrow AL, Shohet RV, Maresh JG. Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiol Genomics 2011;43:1144–1152.
   Google Scholar
• Seki N, Hashimoto N, Sano H, Horiuchi S, Yagui K, Makino H, Saito Y. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism 2003;52:1558–1563.
   PubMedGoogle Scholar
• Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67–75.
   PubMed Web of Science ®Google Scholar
• Mackinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013;23: 654–663.
   PubMed Web of Science ®Google Scholar
• de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55–64.
   PubMed Web of Science ®Google Scholar
• Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, Nakayama H. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 2001;276:3195–3202.
   PubMed Web of Science ®Google Scholar
• Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 1995;230:408–415.
   PubMedGoogle Scholar
• Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 2012;42:1151–1161.
   PubMed Web of Science ®Google Scholar
• Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998–15004.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97:889–901.
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117–1128.
   PubMed Web of Science ®Google Scholar
• Hallam KM, Li Q, Ananthakrishnan R, Kalea A, Zou YS, Vedantham S, et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 2010;5:776–784.
   Google Scholar
• Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006; 55:2510–2522.
   PubMed Web of Science ®Google Scholar
• Sorci G, Riuzzi, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013;1833:101–109.
   PubMed Web of Science ®Google Scholar
• Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis 2009; 207:597–602.
   PubMed Web of Science ®Google Scholar
• Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res 2009;82: 371–381.
   PubMed Web of Science ®Google Scholar
• Lal MA, Brismar H, Eklöf AC, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002;61:2006–2014.
   PubMed Web of Science ®Google Scholar
• Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685–E694.
   PubMed Web of Science ®Google Scholar
• Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 2011;121:43–55.
   PubMed Web of Science ®Google Scholar
• Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580–591.
   PubMed Web of Science ®Google Scholar
• Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia 2004;47: 844–852.
   PubMed Web of Science ®Google Scholar
• Lieuw-a-Fa ML, Schalkwijk CG, Engelse M, van Hinsbergh VW. Interaction of Nepsilon(carboxymethyl) lysine- and methylglyoxal-modified albumin with endothelial cells and macrophages. Splice variants of RAGE may limit the responsiveness of human endothelial cells to AGEs. Thromb Haemost 2006;95:320–328.
   Google Scholar
• Pötzsch S, Blankenhorn A, Navarrete Santos A, Silber RE, Somoza V, Simm A. The effect of an AGE-rich dietary extract on the activation of NF-κB depends on the cell model used. Food Funct 2013 [Epub ahead of print].
   PubMedGoogle Scholar
• Neves D, Assunção M, Marques F, Andrade JP, Almeida H. Does regular consumption of green tea influence VEGF and its receptors expression in aged rat erectile tissue?Possible implications in vasculogenic erectile dysfunction progression. AGE 2008;30:217–228.
   Google Scholar
• Higashi T, Sano H, Saishoji T, Ikeda K, Jinnouchi Y, Kanzaki T, et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 1997;46:463–472.
   PubMed Web of Science ®Google Scholar
• Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009;23:1766–1774.
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370:1097–1109.
   PubMed Web of Science ®Google Scholar
• Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, et al. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 2009, 132:96–101.
   PubMedGoogle Scholar
• Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106: 2827–2835.
   PubMed Web of Science ®Google Scholar
• Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001;21:905–910.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011;60:2379–2385.
   PubMed Web of Science ®Google Scholar
• Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587–2593.
   PubMed Web of Science ®Google Scholar
• Emanuele E, Bertona M. Endogenous secretory RAGE as a potential biochemical screening tool for erectile dysfunction. Med Hypotheses 2006;67:668–669.
   PubMedGoogle Scholar
• Semba RD, Ang A, Talegawkar S, Crasto C, Dalal M, Jardack P, et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr 2012;66:3–9.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427–433.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005;1043:461–466.
   PubMed Web of Science ®Google Scholar
• Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009;54: 197–201.
   PubMed Web of Science ®Google Scholar
• Tomada I, Tomada N, Almeida H, Neves D. Energy restriction and exercise modulate Angiopoietins and Vascular Endothelial Growth Factor expression in the cavernous tissue of high-fat diet-fed rats. Asian J Androl 2012;14:635–642.
   PubMedGoogle Scholar
• Tomada I, Fernandes D, Guimarães JT, Almeida H, Neves D. Energy restriction ameliorates Metabolic Syndrome-induced cavernous tissue structural modifications in aged rats. Age (Dordr)2012 [Epub ahead of print].
   Google Scholar
• Maio MT, Hannan JL, Komolova M, Adams MA. Caloric restriction prevents visceral adipose tissue accumulation and maintains erectile function in aging rats. J Sex Med 2012; 9:2273–2283.
   PubMedGoogle Scholar
• Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998;141:61–75.
   PubMed Web of Science ®Google Scholar
• Woods TM, Kamalov M, Harris PW, Cooper GJ, Brimble M. Synthesis of monolysyl advanced glycation endproducts and their incorporation into collagen model peptides. Org Lett 2012;14:5740–5743.
   PubMedGoogle Scholar
• Sell DR, Lane MA, Obrenovich ME, Mattison JA, Handy A, Ingram DK, et al. The effect of caloric restriction on glycation and glycoxidation in skin collagen of nonhuman primates. J Gerontol Biol Sci 2003;58A:508–516.
   Google Scholar
• Azadzoi KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. J Urol 2005;174:386–393.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Radisavljevic ZM, Siroky MB, Azadzoi KM. Dietary antioxidants improve arteriogenic erectile dysfunction. Int J Androl 2011;34:225–235.
   PubMedGoogle Scholar
• Ha US, Koh JS, Kim HS, Woo JC, Kim SJ, Jang H, et al. Cyanidin-3-O-β-D-glucopyranoside concentrated materials from mulberry fruit have a potency to protect erectile function by minimizing oxidative stress in a rat model of diabetic erectile dysfunction. Urol Int 2012;88:470–476.
   PubMedGoogle Scholar
• Forest CP, Padma-Nathan H, Liker HR. Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, crossover study. Int J Impot Res 2007;19:564–567.
   PubMed Web of Science ®Google Scholar
• Achike FI, Kwan CY. Nitric oxide, human diseases and the herbal products that affect the nitric oxide signalling pathway. Clin Exp Pharmacol Physiol 2003;30:605–615.
   PubMed Web of Science ®Google Scholar
• McCann SM, Licinio J, Wong ML, Yu WH, Karanth S, Rettorri V. The nitric oxide hypothesis of aging. Exp Gerontol 1998;33:813–826.
   PubMed Web of Science ®Google Scholar
• Neves D, Tomada I, Assunção M, Marques F, Almeida H, Andrade JP. Effects of chronic red wine consumption on the expression of vascular endothelial growth factor, angiopoietin 1, angiopoietin 2 and its receptors in rat erectile tissue. J Food Science 2010;75:H79–H86.
   Google Scholar
• Lima CF, Pereira-Wilson C, Rattan SI. Curcumin induces heme oxygenase-1 in normal human skin fibroblasts through redox signaling: relevance for anti-aging intervention. Mol Nutr Food Res 2011;55:430–442.
   PubMed Web of Science ®Google Scholar
• Shen LR, Xiao F, Yuan P, Chen Y, Gao QK, Parnell LD et al. Curcumin-supplemented diets increase superoxide dismutase activity and mean lifespan in Drosophila. Age (Dordr)2012 [Epub ahead of print].
   Google Scholar
• Hu TY, Liu CL, Chyau CC, Hu ML. Trapping of methylglyoxal by curcumin in cell-free systems and in human umbilical vein endothelial cells. J Agric Food Chem 2012; 60:8190–8196.
   PubMed Web of Science ®Google Scholar
• Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol 2012;166:2212–2227.
   PubMed Web of Science ®Google Scholar
• Lin J, Tang Y, Kang Q, Chen A. Curcumin eliminates the inhibitory effect of advanced glycation end-products (AGEs) on gene expression of AGE receptor-1 in hepatic stellate cells in vitro. Lab Invest 2012;92:827–841.
   PubMedGoogle Scholar
• Yang Q, Wu S, Mao X, Wang W, Tai H. Inhibition effect of curcumin on TNF-α and MMP-13 expression induced by advanced glycation end products in chondrocytes. Pharmacology 2013;91:77–85.
   PubMed Web of Science ®Google Scholar
• Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B.Arterioscler Thromb Vasc Biol. 1997;17:3406–3413.
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Müller M et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 1997;77:772–782.
   PubMed Web of Science ®Google Scholar
• Olszanecki R, Gebska A, Korbut R. The role of haem oxygenase-1 in the decrease of endothelial intercellular adhesion molecule-1 expression by curcumin. Basic Clin Pharmacol Toxicol. 2007;101:411–415.
   PubMedGoogle Scholar
• Binion DG, Heidemann J, Li MS, Nelson VM, Otterson MF, Rafiee P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol. 2009; 297:G259–268.
   Web of Science ®Google Scholar
• Panicker SR, Kartha CC. Curcumin attenuates glucose- induced monocyte chemoattractant protein-1 synthesis in aortic endothelial cells by modulating the nuclear factor-kappaB pathway. Pharmacology 2010;85:18–26.
   PubMedGoogle Scholar
• Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol. 1998;55:775–783.
   PubMed Web of Science ®Google Scholar
• Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep. 2006;15:1557–1562.
   PubMed Web of Science ®Google Scholar
• Chen YR, Tan TH. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 1998; 17:173–178.
   PubMed Web of Science ®Google Scholar
• Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, Inagi R et al. Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med 2001;31:20–30.
   PubMed Web of Science ®Google Scholar
• Kim DC, Lee W, Bae JS. Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res 2011;60:1161–1168.
   PubMed Web of Science ®Google Scholar
• Han J, Pan XY, Xu Y, Xiao Y, An Y, Tie L et al. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 2012;8: 812–825.
   PubMed Web of Science ®Google Scholar
• Bradford PG. Curcumin and obesity. Biofactors 2013;39: 78–87.
   PubMed Web of Science ®Google Scholar
• Yang Y, Duan W, Liang Z, Yi W, Yan J, Wang N et al. Curcumin attenuates endothelial cell oxidative stress injury through Notch signaling inhibition. Cell Signal 2013;25: 615–629.
   PubMed Web of Science ®Google Scholar
• Yu YM, Lin HC. Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr Metab Cardiovasc Dis 2010;20:125–132.
   PubMed Web of Science ®Google Scholar
• Chen HW, Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 1998;124:1029–1040.
   PubMed Web of Science ®Google Scholar
• Pae HO, Jeong GS, Jeong SO, Kim HS, Kim SA, Kim YC, et al. Roles of heme oxygenase-1 in curcumin-induced growth inhibition in rat smooth muscle cells. Exp Mol Med 2007;39:267–277.
   PubMed Web of Science ®Google Scholar
• Youreva V, Kapakos G, Srivastava AK. Insulin-like growth-factor-1-induced PKB signaling and Egr-1 expression is inhibited by curcumin in A-10 vascular smooth muscle cells. Can J Physiol Pharmacol 2013;91:241–247.
   PubMedGoogle Scholar
• Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 2006;26:85–90.
   PubMed Web of Science ®Google Scholar
• Hua Y, Dolence J, Ramanan S, Ren J, Nair S. Bisdemethoxycurcumin inhibits PDGF-induced vascular smooth muscle cell motility and proliferation. Mol Nutr Food Res 2013 [Epub ahead of print].
   PubMedGoogle Scholar
• Kang ES, Woo IS, Kim HJ, Eun SY, Paek KS, Kim HJ, et al. Up-regulation of aldose reductase expression mediated by phosphatidylinositol 3-kinase/Akt and Nrf2 is involved in the protective effect of curcumin against oxidative damage. Free Radic Biol Med 2007;43:535–545.
   PubMed Web of Science ®Google Scholar
• Meng Z, Yan C, Deng Q, Gao DF, Niu XL. Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-κB pathways. Acta Pharmacol Sin 2013 [Epub ahead of print].
   Google Scholar
• Kapakos G, Youreva V, Srivastava AK. Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells. Can J Physiol Pharmacol 2012;90:1277–1285.
   PubMedGoogle Scholar
• Fleenor BS, Sindler AL, Marvi NK, Howell KL, Zigler ML, Yoshizawa M, Seals DR. Curcumin ameliorates arterial dysfunction and oxidative stress with aging. Exp Gerontol2012 [Epub ahead of print].
   Google Scholar
• Majithiya JB, Balaraman R. Time-dependent changes in antioxidant enzymes and vascular reactivity of aorta in streptozotocin-induced diabetic rats treated with curcumin. J Cardiovasc Pharmacol 2005;46:697–705.
   PubMed Web of Science ®Google Scholar
• Nakmareong S, Kukongviriyapan U, Pakdeechote P, Kukongviriyapan V, Kongyingyoes B, Donpunha W, et al. Tetrahydrocurcumin alleviates hypertension, aortic stiffening and oxidative stress in rats with nitric oxide deficiency. Hypertens Res 2012;35:418–425.
   PubMed Web of Science ®Google Scholar
• Rungseesantivanon S, Thenchaisri N, Ruangvejvorachai P, Patumraj S. Curcumin supplementation could improve diabetes-induced endothelial dysfunction associated with decreased vascular superoxide production and PKC inhibition. BMC Complement Altern Med 2010;10:57.
   PubMed Web of Science ®Google Scholar
• Coban D, Milenkovic D, Chanet A, Khallou-Laschet J, Sabbe L, Palagani A, et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res 2012;56:1270–1281.
   PubMedGoogle Scholar
• Sajithlal GB, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 1998;56:1607–1614.
   PubMed Web of Science ®Google Scholar
• Abdel Aziz MT, Motawi T, Rezq A, Mostafa T, Fouad HH, Ahmed HH, et al. Effects of a water-soluble curcumin protein conjugate vs. pure curcumin in a diabetic model of erectile dysfunction. J Sex Med 2012;9:1815–1833.
   PubMedGoogle Scholar
• Farhangkhoee H, Khan ZA, Chen S, Chakrabarti S. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr Metab 2006;183:27.
   Google Scholar
• Margina D, Gradinaru D, Manda G, Neagoe I, Ilie M. Membranar effects exerted in vitro by polyphenols – quercetin, epigallocatechin gallate and curcumin – on HUVEC and Jurkat cells, relevant for diabetes mellitus. Food Chem Toxicol 2013 [Epub ahead of print].
   Google Scholar
• Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000;274:61–67.
   PubMed Web of Science ®Google Scholar
• Babu PV, Sabitha KE, Srinivasan P, Shyamaladevi CS. Green tea attenuates diabetes induced Maillard-type fluorescence and collagen cross-linking in the heart of streptozotocin diabetic rats. Pharmacol Res 2007;55:433–40.
   PubMed Web of Science ®Google Scholar
• Rajasekar P, Anuradha CV. L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management. Acta Diabetol 2007;44:83–90.
   PubMedGoogle Scholar
• Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:641–646.
   PubMed Web of Science ®Google Scholar
• Gianfrilli D, Lauretta R, Di Dato C, Graziadio C, Pozza C, De Larichaudy J, et al. Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. Andrologia 2012;44:600–604.
   PubMedGoogle Scholar
• Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005;66:1080–1085.
   PubMedGoogle Scholar
• Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20: 1377–1384.
   PubMed Web of Science ®Google Scholar
• Gentile V, Antonini G, Antonella Bertozzi M, Dinelli N, Rizzo C, Ashraf Virmani M, Koverech A. Effect of propionyl-L-carnitine, L-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes. Curr Med Res Opin 2009;25:2223–2228.
   PubMed Web of Science ®Google Scholar
• Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 2007; 52:1768–1774.
   PubMed Web of Science ®Google Scholar
• Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996;220: 113–119.
   PubMedGoogle Scholar
• Avena R, Arora S, Carmody BJ, Cosby K, Sidawy NA. Thiamine (Vitamin B1) protects against glucose- and insulin-mediated proliferation of human infragenicular arterial smooth muscle cells. Ann Vasc Surg 2000;14:37–43.
   PubMedGoogle Scholar
• Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20:330–336.
   PubMed Web of Science ®Google Scholar
• Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012;7:e40427.
   Google Scholar
• Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003; 63:2123–2133.
   PubMed Web of Science ®Google Scholar
• Chang KC, Liang JT, Tsai PS, Wu MS, Hsu KL. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol 2009;157:1419–1426.
   PubMedGoogle Scholar
• Wu ET, Liang JT, Wu MS, Chang KC. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation. Exp Gerontol 2011;46:482–488.
   PubMedGoogle Scholar
• Watson AM, Soro-Paavonen A, Sheehy K, Li J, Calkin AC, Koitka A, et al. Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2011;54:681–689.
   PubMedGoogle Scholar
• Jain SK, Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 2001;30:232–237.
   PubMed Web of Science ®Google Scholar
• Giannoukakis N. Pyridoxamine (BioStratum). Curr Opin Investig Drugs 2005;6:410–418.
   PubMedGoogle Scholar
• Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:131–136.
   PubMed Web of Science ®Google Scholar
• Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27: 605–614.
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481–1490.
   PubMed Web of Science ®Google Scholar
• Keegan A, Cotter MA, Cameron NE. Corpus cavernosum dysfunction in diabetic rats: effects of combined alpha-lipoic acid and gamma-linolenic acid treatment. Diabetes Metab Res Rev 2001;17:380–386.
   PubMedGoogle Scholar
• Hipkiss AR. Carnosine and its possible roles in nutrition and health. Adv Food Nutr Res 2009;57:87–154.
   PubMedGoogle Scholar
• Krajcovicová-Kudlácková M, Sebeková K, Schinzel R, Klvanová J. Advanced glycation end products and nutrition. Physiol Res 2002;51:313–316.
   PubMed Web of Science ®Google Scholar
• Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995;1:1057–1061.
   PubMed Web of Science ®Google Scholar
• Tan D, Wang Y, Lo CY, Sang S, Ho CT. Methylglyoxal: its presence in beverages and potential scavengers. Ann N Y Acad Sci 2008;1126:72–75.
   PubMed Web of Science ®Google Scholar
• Ruhs S, Nass N, Somoza V, Friess U, Schinzel R, Silber RE, Simm A. Maillard reaction products enriched food extract reduce the expression of myofibroblast phenotype markers. Mol Nutr Food Res 2007;51:488–495.
   PubMedGoogle Scholar
• Leuner B, Ruhs S, Brömme HJ, Bierhaus A, Sel S, Silber RE, et al. RAGE-dependent activation of gene expression of superoxide dismutase and vanins by AGE-rich extracts in mice cardiac tissue and murine cardiac fibroblasts. Food Funct 2012;3:1091–1098.
   PubMedGoogle Scholar
• Ruhs S, Nass N, Bartling B, Brömme HJ, Leuner B, Somoza V, et al. Preconditioning with Maillard reaction products improves antioxidant defence leading to increased stress tolerance in cardiac cells. Exp Gerontol 2010;45: 752–762.
   PubMedGoogle Scholar
• Anton PM, Craus A, Niquet-Léridon C, Tessier FJ. Highly heated food rich in Maillard reaction products limit an experimental colitis in mice. Food Funct 2012;3:941–949
   PubMedGoogle Scholar
• Niebauer J, Maxwell AJ, Lin PS, Wang D, Tsao PS, Cooke JP. NOS inhibition accelerates atherogenesis: reversal by exercise. Am J Physiol Heart Circ Physiol 2003; 285:H535–H540.
   Google Scholar
• Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D’Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978–2984.
   PubMed Web of Science ®Google Scholar
• Boor P, Celec P, Behuliak M, Grancic P, Kebis A, Kukan M, et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009;58:1669–1677.
   PubMed Web of Science ®Google Scholar
• Choi KM, Han KA, Ahn HJ, Hwang SY, Hong HC, Choi HY, et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab 2012;97:3751–3758.
   PubMed Web of Science ®Google Scholar
• Kotani K, Caccavello R, Sakane N, Yamada T, Taniguchi N, Gugliucci A. Influence of physical activity intervention on circulating soluble receptor for advanced glycation end products in elderly subjects. J Clin Med Res 2011;3:252–257.
   PubMedGoogle Scholar
• Lu J, Gong D, Choong SY, Xu H, Chan YK, Chen X, et al. Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. Diabetologia 2010;53:1217–1226.
   PubMed Web of Science ®Google Scholar
• Koupparis AJ, Jeremy J, Angelini G, Persad R, Shukla N. Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit. BJU Int 2006;98:440–444.
   PubMed Web of Science ®Google Scholar
• Keegan A, Cotter MA, Cameron NE. Effects of chelator treatment on aorta and corpus cavernosum from diabetic rats. Free Radic Biol Med 1999;27:536–543.
   PubMedGoogle Scholar
• Gur S, Kadowitz PJ, Hellstrom WJ. A critical appraisal of erectile function in animal models of diabetes mellitus. Int J Androl 2009;32:93–114.
   PubMedGoogle Scholar
• Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70: 138–151.
   PubMed Web of Science ®Google Scholar
• Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999;48:1141–1145.
   PubMed Web of Science ®Google Scholar
• Szabó C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Salzman AL, Radi R. Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem 1997;272:9030–9036.
   PubMed Web of Science ®Google Scholar
• Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product inhibitors. J Biol Chem 2001;276:48967–48972.
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:31–40.
   PubMed Web of Science ®Google Scholar
• Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629–1632.
   PubMed Web of Science ®Google Scholar
• Sell DR, Nelson JF, Monnier VM. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J Gerontol A Biol Sci Med Sci 2001;56:B405–B411.
   PubMed Web of Science ®Google Scholar
• Griffiths MJ, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993;110:963–968.
   PubMed Web of Science ®Google Scholar
• Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119–125.
   PubMed Web of Science ®Google Scholar
• Wessells H, Teal TH, Luttrell IP, Sullivan CJ. Effect of endothelial cell-based iNOS gene transfer on cavernosal eNOS expression and mouse erectile responses. Int J Impot Res 2006;18:438–445.
   PubMed Web of Science ®Google Scholar
• Usta MF, Bivalacqua TJ, Yang DY, Ramanitharan A, Sell DR, Viswanathan A, et al. The protective effect of aminoguanidine on erectile function in streptozotocin diabetic rats. J Urol 2003;170:1437–1442.
   PubMedGoogle Scholar
• Usta MF, Bivalacqua TJ, Koksal IT, Toptas B, Surmen S, Hellstrom WJ. The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment. BJU Int 2004;94:429–432.
   PubMed Web of Science ®Google Scholar
• Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813–1823.
   PubMed Web of Science ®Google Scholar
• Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation end product cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000;97:2809–2813.
   PubMed Web of Science ®Google Scholar
• Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, Hellstrom WJ. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006;3:242–250.
   PubMed Web of Science ®Google Scholar
• Gurbuz N, Sagdic G, Sanli A, Ciftcioglu A, Bassorgun I, Baykal A, Usta MF. Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. Int J Impot Res 2012;24:114–121.
   PubMedGoogle Scholar
• Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011;13:899–908.
   PubMed Web of Science ®Google Scholar
• Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58:31–39.
   PubMedGoogle Scholar
• Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte MR, Varricchio G, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998;28:441–446.
   PubMed Web of Science ®Google Scholar
• Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2012 [Epub ahead of print].
   PubMedGoogle Scholar
• Beisswenger PA, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systematic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198–202.
   PubMed Web of Science ®Google Scholar
• Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003;29:6S95–103.
   Web of Science ®Google Scholar
• Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 2011;93:56–62.
   PubMed Web of Science ®Google Scholar
• Kim YW, Park SY, Kim JY, Huh JY, Jeon WS, Yoon CJ, et al. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats. J Androl 2007;28: 555–560.
   PubMedGoogle Scholar
• Rey-Valzacchi GJ, Costanzo PR, Finger LA, Layus AO, Gueglio GM, Litwak LE, Knoblovits P. Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study. J Androl 2012;33:608–614.
   Google Scholar
• Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000;301:65–77.
   PubMed Web of Science ®Google Scholar
• Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 2006;98:116–124.
   PubMed Web of Science ®Google Scholar
• Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone. BJU Int 2007;100:867–874.
   PubMed Web of Science ®Google Scholar
• Gholamine B, Shafiei M, Motevallian M, Mahmoudian M. Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study. J Pharm Pharm Sci 2008;11:22–31.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up- regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clin Exp Med 2011;11:131–135.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012;72:2365–2373.
   PubMed Web of Science ®Google Scholar
• Long SB, Blaha MJ, Blumenthal RS, Michos ED. Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly. Clin Interv Aging 2011;6:27–35.
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Margaritis M, Shirodaria C, Antoniades C. Translating the effects of statins: From redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012;108:840–848.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?J Mol Cell Cardiol 2012;52:83–92.
   PubMed Web of Science ®Google Scholar
• Ishida K, Matsumoto T, Taguchi K, Kamata K, Kobayashi T. Pravastatin normalizes endothelium-derived contracting factor-mediated response via suppression of Rho-kinase signalling in mesenteric artery from aged type 2 diabetic rat. Acta Physiol 2012;205:255–265.
   PubMedGoogle Scholar
• Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928–1930.
   PubMed Web of Science ®Google Scholar
• Santilli F, Bucciarelli L, Noto D, Cefalù AB, Davì V, Ferrante E, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007;43:1255–1262.
   PubMed Web of Science ®Google Scholar
• Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010;209:173–177.
   PubMed Web of Science ®Google Scholar
• Jinnouchi Y, Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi T. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006;6:191–193.
   PubMed Web of Science ®Google Scholar
• Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010;142:273–278.
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Yoon YW, Lee BK, Kwon HM, Hwang KC, Kim M, et al. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med 2009;41:802–811.
   PubMed Web of Science ®Google Scholar
• Feng B, Xu L, Wang H, Yan X, Xue J, Liu F, Hu JF. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim Biophys Acta 2011;1812:1130–1137.
   PubMedGoogle Scholar
• Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004;172:255–258.
   PubMed Web of Science ®Google Scholar
• Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction?A systematic review. Fam Pract 2002;19:95–98.
   PubMed Web of Science ®Google Scholar
• Trivedi D, Kirby M, Wellsted DM, Ali S, Hackett G, O’Connor B, van Os S. Can simvastatin improve erectile function and health-related quality of life in men aged ≥ 40 years with erectile dysfunction? Results of the Erectile Dysfunction and Statins Trial [ISRCTN66772971]. BJU Int 2012 [Epub ahead of print].
   Google Scholar
• Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 2004;498:189–194.
   PubMed Web of Science ®Google Scholar
• Dadkhah F, Safarinejad MR, Asgari MA, Hosseini SY, Lashay A, Amini E. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010;22:51–60.
   PubMed Web of Science ®Google Scholar
• Herrmann HC, Levine LA, Macaluso J Jr, Walsh M, Bradbury D, Schwartz S, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil?Hypothesis and pilot trial results. J Sex Med 2006;3:303–308.
   Google Scholar
• Bank AJ, Kelly AS, Kaiser DR, Crawford WW, Waxman B, Schow DA, Billups KL. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006; 11:251–257.
   PubMedGoogle Scholar
• Fibbi B, Morelli A, Marini M, Zhang XH, Mancina R, Vignozzi L, et al. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl 2008;29:70–84.
   PubMedGoogle Scholar
• Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363–2372.
   PubMed Web of Science ®Google Scholar
• Schlimmer N, Kratz M, Böhm M, Baumhäkel M. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol 2011; 163:804–814.
   PubMedGoogle Scholar
• Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, et al.; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010;121:1439–1446.
   PubMed Web of Science ®Google Scholar
• Simm A, Wagner J, Gursinsky T, Nass N, Friedrich I, Schinzel R, et al. Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?Exp Gerontol 2007;42:668–675.
   PubMed Web of Science ®Google Scholar
• Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 2002;14:178–188.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Henderson L. Sexual function in patients with chronic angina pectoris. Am J Cardiol2013 [Epub ahead of print].
   Google Scholar
• Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42–48.
   PubMed Web of Science ®Google Scholar